A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 14,795 shares of PRPH stock, worth $4,438. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,795
Holding current value
$4,438
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$0.28 - $0.55 $4,142 - $8,137
14,795 New
14,795 $7,000
Q4 2022

Feb 08, 2023

BUY
$8.78 - $12.47 $49,887 - $70,854
5,682 Added 22.67%
30,744 $296,000
Q3 2022

Oct 17, 2022

BUY
$8.96 - $14.7 $106,193 - $174,224
11,852 Added 89.72%
25,062 $0
Q2 2022

Jul 13, 2022

BUY
$6.52 - $13.24 $86,129 - $174,900
13,210 New
13,210 $167,000

Others Institutions Holding PRPH

About ProPhase Labs, Inc.


  • Ticker PRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 16,024,400
  • Market Cap $4.81M
  • Description
  • ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...
More about PRPH
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.